Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TSPAN1
REST API REST API
Homo sapiens
TSPAN1 is differentially expressed in 218 experiments: 122 organism parts: kidney, lung, ... (120 more);, 132 disease states: normal, prostate carcinoma, ... (130 more);, 60 cell types 471 cell lines 27 compound treatments and 63 other conditions.
Synonyms NET-1, TSPAN-1
Orthologs Tspan1 (Rattus norvegicus)   TSN1_BOVIN (Bos taurus)   TSPAN1 (Gallus gallus)   TSPAN1 (Danio rerio)   Tspan1 (Mus musculus)   Tsp96F (Drosophila melanogaster)   tspan1 (Xenopus laevis)   TSPAN1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term membrane, lysosomal membrane, integral to membrane
InterPro Term Tetraspanin, Tetraspanin_subgr
UniProt Accession O60635
Search EB-eye ENSG00000117472
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (35 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
LNCaP
2
E-GEOD-14464, E-GEOD-14990
BT-474
2
E-GEOD-3529, E-GEOD-5823
HL-60
2
E-GEOD-5258, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDAMB453
2
E-MTAB-37, E-MTAB-62
465 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-19397, E-GEOD-3920, E-GEOD-13987, E-GEOD-21750, ... (31 experiments)

Factor Value U/D Experiments
stromal cell
3
E-MEXP-2034, E-MEXP-1327, E-GEOD-3998
macrophage
1
2
E-GEOD-22373, E-GEOD-8286, E-GEOD-3982
n/a
1
E-MTAB-24
cancer cell culture
1
E-GEOD-14990
interstitial stromal cells
1
E-GEOD-20758
activated B-cell
1
E-MEXP-2360
54 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-TABM-26, E-GEOD-20602, ... (41 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
5
E-GEOD-7307, E-MTAB-62, E-MEXP-1327, E-MTAB-37, E-GEOD-96, ... (6 experiments)
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-57
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
adenocarcinoma
1
2
E-MTAB-37, E-MTAB-62, E-MEXP-1331
126 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-6907, E-GEOD-15205, E-GEOD-5741, E-GEOD-5824, ... (18 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-412, E-GEOD-5824, E-GEOD-4668, E-GEOD-6907, E-GEOD-5741 ... (5 experiments)
Ethanol
1
E-MEXP-2417
glutamine
1
E-MEXP-1335
unknown
1
E-GEOD-7307
TGF
1
E-GEOD-15205
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
21 more value(s).


Biosource provider

studied in E-MTAB-37

Factor Value U/D Experiments
DSMZ
1
E-MTAB-37
ECACC
1
E-MTAB-37


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-22513, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MTAB-62 ... (5 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MTAB-108, E-GEOD-6431, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-TABM-763, E-GEOD-17476, E-TABM-321, E-TABM-601, E-GEOD-1153, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-1446

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276, E-GEOD-20194, E-GEOD-16716, ... (6 experiments)

Individual
studied in E-MTAB-197, E-GEOD-5764, E-TABM-176, E-GEOD-1926, E-GEOD-19519, ... (23 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Subtype
studied in E-GEOD-24283

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-4922

Processing time: 0.292 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM